Skip to content

Author

L. Mielniczuk

We have 2 of 6 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial

Treatment with mitiperstat, intended to target the neutrophil–MPO inflammatory pathway, did not improve symptoms or exercise function in individuals with heart failure with preserved or mildly reduced ejection fraction.

Lars H. Lund, Carolyn S. P. Lam, P. E. Pizzato et al. · 1 citation
Open access Sep 2026

Epigenetic signatures of biological vulnerability and residual risk in heart failure

Higher epigenetic age and DNAm scores for CRP, frailty, and mortality were associated with increased risk, whereas higher diet-related DNAm scores were inversely associated, particularly for all-cause death.

P. Meyre, M. Chong, E. Shemesh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.